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Abstract
The combination of passive drug permeability, affinity for uptake and efflux transporters as
well as gastrointestinal metabolism defines net drug absorption. Efflux mechanisms are
often overlooked when examining the absorption phase of drug bioavailability. Knowing the
affinity of antimalarials for efflux transporters such as P-glycoprotein (P-gp) may assist in
the determination of drug absorption and pharmacokinetic drug interactions during oral
absorption in drug combination therapies. Concurrent administration of P-gp inhibitors and
P-gp substrate drugs may also result in alterations in the bioavailability of some antimalari-
als. In-vitro Caco-2 cell monolayers were used here as a model for potential drug absorption
related problems and P-gp mediated transport of drugs. Artemisone had the highest perme-
ability at around 50 x 10−6 cm/sec, followed by amodiaquine around 20 x 10−6 cm/sec; both
mefloquine and artesunate were around 10 x 10−6 cm/sec. Methylene blue was between 2
and 6 x 10−6 cm/sec depending on the direction of transport. This 3 fold difference was able
to be halved by use of P-gp inhibition. MRP inhibition also assisted the consolidation of the
methylene blue transport. Mefloquine was shown to be a P-gp inhibitor affecting our P-gp
substrate, Rhodamine 123, although none of the other drugs impacted upon rhodamine123
transport rates. In conclusion, mefloquine is a P-gp inhibitor and methylene blue is a partial
substrate; methylene blue may have increased absorption if co-administered with such P-
gp inhibitors. An upregulation of P-gp was observed when artemisone and dihydroartemisi-
nin were co-incubated with mefloquine and amodiaquine.
Introduction
TheWorld Health Organization recommends drug combinations over single therapy in the
management of uncomplicated Plasmodium falciparummalaria where a short acting artemisi-
nin derivative is recommended to be combined with a long acting antimalarial [1].
Development of drug resistance is a major problem in the management of malaria and there
are reports of increased resistance for existing artemisinin combination therapies [2–4].
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Antagonistic pharmacokinetic interactions are possible in antimalarial combination therapy
and this could be drug absorption related. Hence it is important to look at the drug permeabil-
ity and efflux mediated transport of available antimalarial drugs. Clear evidence of the pharma-
cokinetics of antimalarials helps in the design of optimum dosage regimens which indirectly
assists to combat the development of drug resistance in antimalarial therapy.
P-glycoprotein (P-gp) drug interactions result from concurrent administration of P-gp
substrates and inhibitors [5, 6] where circulating drug concentrations are increased. Pre-expo-
sure to P-gp inducers could alternatively lead to decreases in absorption of a P-gp substrate
[7]. This could be a potential issue for antimalarial drugs as combinations are common for
malaria therapy, as well as being commonly applied over existing maladies with their own
therapies. Patients in Africa and South East Asia where malaria is endemic are likely to be
treated for multiple conditions, resulting in a high probability of them being on multiple med-
ications while being treated with antimalarials. For example, many antivirals used in HIV
antiretroviral therapy are identified as P-gp substrates and concurrent administration of such
antivirals and antimalarial drugs [8–10] can result in an unexpected increase in systemic avail-
ability of the P-gp substrate.
Evidence of active efflux protein involvement either through substrate action, inhibition of
transporters or regulation of activity for many antimalarial is very limited and little informa-
tion of this relates to combination therapy, especially given that the current paradigm for Plas-
modium falciparum therapy, artesunate is combined with either mefloquine or amodiaquine
[1]. In addition a new artemisinin derivative, artemisone with improved efficacy and reduced
neurotoxicity has been introduced [11–13]. It is proposed that artemisone can be given in com-
bination with long acting quinoline derivatives such as amodiaquine and mefloquine [14].
Methylene blue treatment for malaria is being revisited and clinical trials have found superior
efficacy of methylene blue plus amodiaquine therapy compared to artesunate plus amodia-
quine therapy [15]. The permeability data and P-gp related interactions for these new potential
therapies using artemisone and methylene blue have not been reported previously.
Apart from in-vivo studies, in-vitro studies based on gastrointestinal epithelia cells are used
for prediction of drug permeability [16]. Caco-2 cell monolayers are the most commonly
adopted in-vitro cell model to identify drug absorption related issues and is comparable to
more complex models such as in-situ perfusion model [17, 18]. The apparent permeability
(Papp) values generated based on this model can be used to classify low, medium and high per-
meable drugs which in turn predicts the in-vivo drug absorption of the drug [16].
Hence it was aimed to determine the P-gp inhibitory, substrate and inducing properties and
gastrointestinal permeability of artesunate, mefloquine and amodiaquine as well as the newly
introduced artemisone and methylene blue in single and/or combination therapy using the in-
vitro Caco-2 cell line.
Materials and Methods
Drugs
Artemisinin, mefloquine hydrochloride, amodiaquine dihydrochloride dihydrate, artesunate,
dihydroartemisinin, sodium orthovanadate, rhodamine123 (rh123) and rifampicin were pur-
chased from Sigma Aldrich (St Louis, MO, USA). Methylene blue zinc chloride double salt was
purchased from Fluka Sigma Aldrich (Steinem, Switzerland). Artemisone was kindly donated
by Professor Richard Haynes, The Hong Kong University of Science and Technology, Hong
Kong. Vinblastine hydrochloride was purchased from ICN biochemical (Seven hills, NSW,
Australia). PSC 833 was donated from Novartis BioPharma (Basel, Switzerland). GF 120918
was donated from Glaxo-SmithKline (Boronia, Vic, Australia) and MK571 was supplied by
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BIOMOL international (Plymouth meeting, Philadelphia). Mini Protease inhibitor tablets were
supplied by Thermo Scientific (Rockford, USA).
Chemicals
Acetonitrile, methanol and ethanol were supplied from Fisher Scientific (Fair Lawn NJ, USA).
Dimethyl sulfoxide was purchased from Ajax Finechem (NSW, Australia). TRIS hydrochloride
was purchased from Ultrapure bio-reagents (NJ, USA) and sodium chloride, sodium potassium
tartrate and copper (II) sulphate were purchased from Chem-Supply (Gillman, SA). Sodium
dodecyl sulphate, sodium carbonate, casein, potassium dihydrogen ortho phosphate (KH2PO4),
trifluroacetic acid, phosphoric acid (H3PO4), formic acid and nonidet P40 substitute were sup-
plied by Sigma Aldrich (MO, USA). Sodium hydroxide and Folin’s reagent were supplied by
BDHMerck Pvt Ltd (Victoria, Australia). All other chemicals were of analytical grade.
Cells and cell culture reagents
The human colon carcinoma cell lines (Caco-2) were obtained from American Type Culture
Collection (ATCC), University Boulevard (Manassas, VA, USA) and Hela-MDR-off trans-
fected cells were gifted from Professor Michael Gottesman, NIH, Bethesda, USA. High glucose
Dulbecco’s modified eagle medium, Dulbecco’s phosphate buffered saline (PBS), L-Glutamine,
Hanks buffered salt solution (HBSS), N-2-hydroxyethylpiperazine -N'-2-ethane sulphonic
acid, Trypan blue stain (0.4%) and TrypLE Express were supplied by Gibco [Life Technologies
(NY, USA)]. Glucose was purchased from APS Finechemicals (NSW, Australia). Non-essential
amino acid, penicillin G (10,000 u/mL) and streptomycin (10,000 μg/mL) were purchased
from Trace Biosciences (Castle Hill, NSW, Australia). Foetal calf serum (FCS) was obtained
from the SerANA (Bunbury, Western Australia).
Western blots were conducted using BOLT 4–12% Bis-Tris preformed gels and NuPAGE
MOPS running buffer, SeeBlue Plus2 Pre-stained Standard purchased from Novex by Life tech-
nologies (CA, USA). MDR1 mouse monoclonal antibody was purchased from Santa Cruz Bio-
technology Inc. (California, USA). Monoclonal Anti-β-Actin antibody produced in mouse was
supplied by Sigma Aldrich (MO, USA). Goat anti-mouse secondary antibodies were purchased
from Jackson ImmunoResearch Laboratories Inc (West Grove, PA, USA). Clarity Western
ECL substrate was supplied by BIORAD Laboratories Inc. (USA).
Bidirectional transport studies
The Caco-2 cells were seeded on 0.6 cm2 0.4 μMMillipore PCF™ filter inserts at the cell density
of 65,000 cells/cm2 as done previously in the lab [19]. Briefly, the cells were grown for 21–24
days to allow full maturation and formation of tight monolayers [20–22]. The initial experi-
ments were conducted in mid-40s passage cells and repeated in early 80s passage Caco-2 cells
[23]. The Trans epithelial electrical resistance (TEER) was measured immediately before and
after the experiment using an epithelial voltage/ohm meter and an ENDOHM 12 chamber
(World precision instruments, Sarasota, FL). TEER values were measured both before and after
the study with readings above 300Ω.cm2 considered as acceptable for tight junctions [22]. In
experimental conditions, the blank millicell filter inserts consistently provided minimum resis-
tance with Papp greater than 60 x10
-6 cm/sec and no TEER value. Medium alone gave a reading
of 6–7Ω.cm2. In order to maintain equivalent transport medium (HBSS/HBSS with inhibitor)
level both outside and inside the chambers, 300 μL was used as medium in the apical chambers
and 600 μL in the basolateral chambers. This negated any pressure differential complicating
drug diffusion analysis. The P-gp inhibitory and substrate properties of antimalarials were
determined by co-incubation of the drug (less than 1% ethanol was used as the co-solvent)
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with a known P-gp substrate, rhodamine 123, and known P-gp inhibitor, PSC 833 respectively,
as used previously [23, 24]. Drugs were co-incubated with MRCP, BCRP and ATP hydrolysis
blockers to determine the involvement of other efflux mechanisms. Prior to the experiment,
the transport medium, HBSS or HBSS with P-gp inhibitors were pre-incubated with the cells
for 30 minutes. Following incubation, inserts were placed in new well plates and donor cham-
ber is replaced with drug or drug with inhibitor and the receiver chamber with blank HBSS or
HBSS with inhibitor. Transport medium was collected from the receiver chamber after stirring
at time intervals of 30, 60, 90 and 120 minutes and was replaced with the same volume of fresh
HBSS, or HBSS with inhibitor, when P-gp inhibitors were used in the study. At the end of the
experiment 100 μL of medium was removed from the donor chamber in addition to medium
collected from the receiver chamber during the study. The cells were then washed thoroughly
in cold (4°C) PBS and cell membranes attached to the inserts were sonicated for 10 minutes in
a sonicating water bath and centrifuged at 10,000 g for 10 minutes. Supernatant was frozen at
-80°C until assayed. The Papp values of three well plates were determined using methods modi-
fied from Artursson’s group [25, 26] as described by Crowe and Lemaire [27]. Our modified
equation accounts for the amount of drug accumulated in the cells at the end of the experi-
ment, and estimates the changes in donor concentration over the course of the study to
improve the accuracy of each clearance value attained during the 2 to 3 hour efflux studies.
CL:vol ¼ Aa=f½Cd0  Vd  ½Aa þ ðCa  VsÞ  ðAcÞ  n=nfin=Vdg
CL.vol = clearance volume (mL), n = time (min), Aa = amount in acceptor compartment at
time n (pmols), Cd0 = concentration in donor compartment at time zero (nM), Vd = volume of
the donor compartment (mL), Ca = concentration in acceptor compartment at the previous time
point (nM), Vs = sample volume of previous time point (mL), Ac = amount of compound associ-
ated with the cells (pmol), Nfin = final time point (min). Papp = Apparent permeability (cm/sec)
Rate of clearance ðmL=minÞ ¼ CL:vol = n
Papp ðcm=secÞ ¼ Rate of clearance = Surface area ðcm2Þ
The cleared volume was plotted against time and the slope of the regression line was divided
by the surface area to obtain the Papp values. The mean Papp values for both Ap-Bas (N = 3)
and Bas-Ap (N = 3) directions plus standard error were presented as the bidirectional transport
values of the study drugs. Mean Papp for Bas-Ap direction was divided by the Ap-Bas direction
to obtain the efflux ratio and values above two were considered as drugs having true efflux
transport [28]. At the end of the experiment, the total recovery/mass balance of the drug was
calculated and results were considered valid if the recovery was> 80%.
Assay techniques
Assay of rhodamine123. Rhodamine123 levels were quantified using a Perkin Elmer
Enspire multi-mode plate reader (Waltham, MA, USA) and measurements were done using
fluorescence detection at excitation and emission wavelengths of 485 and 525 nm respectively.
Assay of mefloquine, amodiaquine and methylene blue using HPLC
Instrumentation. The HPLC analysis was performed using an Agilent 1200 series HPLC
consisting of binary gradient pump with a degasser, auto sampler, a thermostated column oven
and a duel wave length UV detector (Agilent Technology, Waldbronn, Germany). Chemstation
software version, Rev. B. 03.01.SRI was used to process data (Agilent Technology, Waldbronn,
Germany).
P-gp Mediated Antimalarial Transport
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Assay of mefloquine. The method from Davis and colleagues [29] was adopted with slight
modifications. Separations were performed using an Apollo C18 (5 μm, 4.6x150mm) column
attached to a matched guard column (5 μm, 4.6x5.5 mm). The mobile phase consisted of
KH2PO4 (w/v 20 mM) in deionized water (42% v/v) adjusted to pH 3.0 using H3PO4 and aceto-
nitrile (58:42). The mobile phase was pumped at 1mL/min. The injection volume was 40 μL
and column oven was maintained at 35°C. The analytes were detected at 222 nm and the reten-
tion time was 5.6 minutes.
Assay of amodiaquine. Assay developed by Pussard and co-workers [30] were used and
slight modifications were done to adjust laboratory conditions. Separation was done using a
Prevail C18 (3 μm, 4.6x150mm) column attached to a Direct-connect™ universal column prefil-
ter. The mobile phase consisted of 20 mM (w/v) KH2PO4 in deionized water at pH 3.0 and ace-
tonitrile (82:18) v/v. The flow rate was 1 mL/min. The injection volume was 40 μL and column
oven was maintained at 30°C. The analytes were detected at 343 nm with a retention time of
2.4 minutes.
Assay of methylene blue. Methylene blue detection was based on a method by Peter and
colleagues [31]. Separations were performed using an Apollo C18 (5 μm, 4.6x150mm) column
attached to matched guard column (5 μm, 4.6x5.5mm). The mobile phase consisted of 60% 20
mM (w/v) KH2PO4 adjusted to pH 3 using H3PO4, 35% acetonitrile and 5% methanol which
was pumped at 1 mL/min. The injection volume was 40 μL and column oven was maintained
at 30°C. The analytes were detected at 660 nm with a retention time of 3.8 minutes.
Assay of artesunate and artemisone using LC-MS-MS
Instrumentation. The UPLC-MS-MS system consisted of Nexera UPLC (LC-30A), degas-
ser (DGU-20A5), autosampler (SIL-30A) and column oven (CTO-30A) coupled with a Shi-
madzu triple Quadrupole Mass Spectrometer (model 8030 Shimadzu, Kyoto, Japan). Electro
Spray Ionisation (ESI) and Atmospheric Pressure Chemical Ionisation (APCI) interfaces were
included in the system.
Salt removal. A 40 μL sample was spiked with 5 μL 0.5 mM artemisinin internal standard.
The sample was pre-treated with 4 μL of 1% trifluroacetic solution by pipetting in and out
many times. Agilent Bond Elute OMIX 96 C4 100 μL pipette tips were used for removing salt
content in HBSS in which the drug was dispersed. The pipettor was adjusted to the maximum
volume (100 μL). The tips were conditioned by aspirating and discarding the conditioning
solution (50% acetonitrile in water) and the process was repeated. The tip was washed by aspi-
rating and discarding 0.1% trifloroacetic acid solution in water and repeating.
Pre-treated samples were loaded into the tips by gently aspirating and discarding into the
same vial. The process was repeated 10 times in order to increase binding efficiency of drugs
to the OMIX 96 C4 matrix. The tips were washed with washing solution (0.1% trifluroacetic)
by aspiration and discarding four times. The samples were then eluted in 100 μL of the elu-
tion solution (0.1% formic acid in 95% acetonitrile) and 3 μL of the sample was injected into
the LC-MS.
Assay of artesunate. The LC-MS method described by Salman and co-workers [32] were
modified to suit the LC-MS-MS conditions. Chromatographic separation was performed on a
Waters Acquity BEH C18 column (1.7 μm, 2.1x50mm) connected with VanGuard Acquity
UPLC BEH C18 pre-column (1.7 μm, 2.1x5mm) (Waters Corp, Wexford, Co. Wexford, Ire-
land) at 40°C. Mobile phase A consisted of water + 0.1% v/v formic acid and mobile phase B
consisted of acetonitrile + 0.1% v/v formic acid. The analytes were eluted using the gradient;
solvent A: B percentage of 70:30, 5:95, 5:95, 70:30 at 0.5, 3, 4 and 4.1 minutes respectively and
each run was of 6 minutes. Quantitation was performed in multiple reactions monitoring,
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MRMmode, using DUIS (ESI+ and APCI+) ion sources. The Precursor-product ion pairs were
as follows: Artesunate m/z 401.8!267.3 and artemisinin m/z 283!265. The optimized mass
spectra were acquired with an interface voltage of 4.5 kV, a detector voltage of 1.0 kV, a heat
block temperature of 500°C and a desolvation temperature of 160°C. Nitrogen was used as the
nebulizer gas at a flow rate of 3 L/min and drying gas flow was maintained at 8 L/min. Argon
was used as collision gas at 230 Kpa. Dwell time for all the compounds were 100 msec. Colli-
sion energy for artesunate and artemisinin were -11.3 V and -9.2 V, respectively.
Assay of artemisone. This was based on the LC-MS method described by Manning’s
group [33] and modified to suit the LC-MS-MS conditions in our laboratory. Chromatographic
separation was same as for artesunate with minor modification of gradient steps; Solvent A: B
percentage; 50:50, 5:95, 5:95, 50:50 at 0.3, 3, 3.5 and 3.6 minutes, the run was of 5 minutes dura-
tion. Quantitation was performed in multiple reactions monitoring mode, using ESI+ interface.
The Precursor-product ion pairs were as follows: artemisone m/z 402.17!163.4 and artemisi-
nin m/z 283!265. The optimized mass spectra were acquired with an interface voltage of 4.5
kV, a detector voltage of 1.0 kV, a heat block temperature of 300°C and a desolvation tempera-
ture of 180°C. Nitrogen was used as the nebulizer gas at a flow rate of 3 L/min and drying gas
flow was maintained at 12 L/min. Argon was used as collision gas at 230 Kpa. Dwell time for all
the compound were 100 msec. Collision energy for artemisone was -21 V and the collision
energy for artemisinin was -9.1 V.
Determination of P-gp inducing properties of antimalarials
Caco-2 cells were seeded in 6 well plates at 10,000 cells/cm2 for 21 days. Drugs and drug combi-
nations at 20 μM prepared in cell growth medium were added on to the mature cells and
exposed for 96 hours. After drug exposure, cells were washed three times using PBS and cell
lysate was prepared in lysis buffer. The protein content was quantified using the 96 well micro-
Lowry protein assay and regulation of P-gp was determined using western blotting. Up regula-
tion of P-gp was determined by comparing western blot images for treated and control samples
and 1.5 fold higher protein density compared to controls was considered as possible up-regula-
tion of the transporter.
Western blotting. Proteins were separated using 4–12% Bis Tris Plus 15 well Nupage
BOLT gels in Novex Bolt Mini Gel Tanks (Life Technologies, CA, USA) and transfer was done
in a Xcell II Bolt Module (Novex, CA, USA). The membrane was blocked using 2% casein in
TBS and washed with TBST. The primary antibody; Mdr (G-1) mouse monoclonal IgG2b 200
and mouse anti-β actin were used as the antibody for β-actin, the reference protein. The anti-
body; HRP linked goat anti mouse IgG was used as the secondary antibody. The washed mem-
brane was incubated in a BioRad clarity chemiluminescent substrate and enhancer was read
and semi quantified using the BIORAD Chemidoc MPT imager with Image LabTM software.
Data Analysis
Results in this study are presented as the mean ± SEM. Significant differences between values
were examined using Student’s two-tailed unpaired t-test or one way ANOVA with Dunnett’s
post hoc analysis. Results were considered significant if P< 0.05.
Results
P-glycoprotein Inhibitory properties of antimalarial drugs
Our model P-gp substrate, rhodamine123 showed an efflux ratio close to 5 (Table 1). The Papp
for basolateral to apical (Bas-Ap) transport of rh123 was reduced from 2.42 to 1.34 × 10−6 cm/sec
P-gp Mediated Antimalarial Transport
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by mefloquine at 100 μM, halving the efflux ratio (Table 1). Amodiaquine, artesunate and artemi-
sone did not exhibit P-gp inhibitory properties at 100 μM as shown in Table 1. P-gp inhibitory
properties of antimalarials (other than mefloquine) were also tested at 300 μM (Table 1) to
attempt to elicit a response that may allow us to generate a graded response curve to rh123. How-
ever no change in bidirectional transport of rh123 was observed, indicating lack of P-gp inhibi-
tion by these drugs. No additive inhibition of P-gp efflux was observed when mefloquine was
combined with short acting artemisinin derivatives, artesunate and artemisone. This reaffirms
the lack of inhibitory properties by the artemisinin derivatives (Table 1 and Fig 1).
Efflux transport and permeability of antimalarials
Within our laboratory, the threshold Papp values of 1×10
−6 and 25×10−6 cm/sec has been estab-
lished for drugs having low and high permeability and values around 10×10−6 cm/sec is defined
as medium permeability [19, 27]. The extent of drug absorption of low, moderate and high per-
meable drugs are less than 50%, 50–84% and above 85%, respectively [16].
Mefloquine. The apical to basolateral (Ap-Bas) and Bas-Ap directional Papp values of mef-
loquine were found to be in the range of 6 to 10 × 10−6 cm/sec and 5 to 7 × 10−6 cm/sec respec-
tively (Table 2). The efflux ratio was close to unity and incubation with a known P-gp
inhibitor, PSC 833, appeared to change very little of the Papp of mefloquine (Fig 2). Thus meflo-
quine does not exhibit efflux transport, with inherent physiological chemical properties defin-
ing its bidirectional transport at the concentrations tested. The current WHO recommended
antimalarial combinations consist of a short acting artemisinin derivative and long acting
Table 1. Apparent permeability (Papp) and efflux ratio for 5 μM rh123 through Caco-2 cell monolayers when co-incubated with selected antimalarial
drugs.
Rh123+ Drug Ap-Bas (10−6 cm/sec) Bas-Ap (10−6 cm/sec) Efflux ratio Ap-Basa (P value) Bas-Apb (P value)
100 μM antimalarial drugs
Rh123 0.5 ± 0.1 2.4 ± 0.3 4.7
Rh123+PSC 0.5 ± 0.1 0.5 ± 0.0 1.0 0.74 0.003**
Rh123+MQ 0.5 ± 0.0 1.3 ± 0.1 2.3 0.64 0.02*
Rh123+AQ 0.4 ± 0.0 2.4 ± 0.3 5.9 0.14 0.63
Rh123+MB 0.4 ± 0.0 3.0 ± 0.3 6.7 0.24 0.21
Rh123+ ART 0.5 ± 0.0 2.3 ± 0.3 5.2 0.32 0.88
Rh123+ AM 0.5 ± 0.1 2.0 ± 0.1 4.3 0.54 0.27
Rh123 + ART + MQ 0.5 ± 0.1 1.3 ± 0.1 2.4 0.81 0.02*
Rh123 + AM + MQ 0.5 ± 0.0 1.5 ± 0.2 3.3 0.43 0.05*
300 μM antimalarial drugs
Rh123 0.5 ± 0.1 2.8 ± 0.6 5.7
Rh123+ AQ 0.5 ± 0.1 2.6 ± 0.1 5.0 0.95 0.09
Rh123+ ART 0.4 ± 0.0 2.9 ± 0.2 7.5 0.07 0.22
Rh123+AM 0.5 ± 0.1 3.0 ± 0.1 5.6 0.70 0.24
Rh123+MB 0.5 ± 0.0 2.9 ± 0.1 5.3 0.56 0.71
Data is presented as Permeability +/- SEM.
*P values < 0.05 are deemed significant in their difference.
rh123: rhodamine123, PSC: PSC833, MQ: mefloquine, AQ: Amodiaquine, MB: methylene blue, AM: artemisone.
a Papp Ap-Bas of rhodamine123 alone was compared with Ap-Bas of rhodamine123 in combination.
b Papp Bas-Ap of rhodamine123 alone was compared with Bas-Ap of rhodamine123 in combination.
** Significant at the level of P < 0.005
doi:10.1371/journal.pone.0152677.t001
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Fig 1. A). Ap-Bas (striped square) and Bas-Ap (solid diamond) transport of rhodamine123 alone, Ap-Bas (hashed square) and Bas-Ap (open diamond)
transport of rhodamine123 when combined with mefloquine B). Ap-Bas (hashed square) and Bas-Ap (open diamond) transport of rhodamine123 when
combined with mefloquine compared to Ap-Bas (solid square) and Bas-Ap (hashed diamond) transport of rhodamine123 when co-incubated with mefloquine
and artesunate (N = 3, Mean ±SEM)
doi:10.1371/journal.pone.0152677.g001
Table 2. Apparent permeability (Papp) and efflux ratio of antimalarials through Caco-2 cell monolayers.
Drug Conc (μM)+ inhibitor (μM) Ap-Bas (10−6 cm/sec) Bas-Ap (10−6 cm/sec) Efflux ratioa Net flow direction (P valueb)
MQ 10 9.9 ± 0.7 6.6 ± 0.4 0.7 Diffusion (0.02)*
MQ + PSC 10 + 4 11.0 ± 0.4 12.0 ± 1.0 1.0 Diffusion (0.4)
MQ 20b 5.8 ± 0.7 5.3 ± 0.9 0.9 Diffusion (0.66)
MQ + PSC 20 + 4 6.5 ± 0.4 7.6 ± 0.2 1.2 Diffusion (0.44)
MQ 100 8.9 ± 0.7 11.4 ± 0.8 1.2 Diffusion (0.08)
MQ + PSC 100 + 4 11.1 ± 0.1 12.4 ± 0.4 1.1 Efflux (0.04)*
MQ + ART 10 + 10 14.4 ± 1.2 8.6 ± 0.7 0.6 Diffusion (0.01)*
MQ+ MB 50 + 100 8.1 ± 0.3 9.0 ± 1.1 1.1 Diffusion (0.79)
MQ + AM 50 + 20 6.7 ± 1.2 6.3 ± 0.6 0.9 Diffusion (0.49)
AQ 10 16.0 ± 1.1 21.5 ± 0.9 1.3 Efflux (0.02)*
AQ 100 22.5 ± 2.0 23.3 ± 0.8 1.0 Diffusion (0.74)
AQ + PSC 100 24.5 ± 2.0 26.7 ± 0.7 1.1 Diffusion (0.36)
AQ + AM 10 + 10 16.7 ± 0.7 18.3 ± 2.6 1.1 Diffusion (0.52)
ART 50 10.2 ± 0.3 12.3 ± 0.1 1.2 Efflux (0.002)*
ART + PSC 50 + 4 5.9 ± 0.1 9.1 ± 1.1 1.5 Efflux (0.05)*
ART +MQ 50 + 50 8.5 ± 0.2 9.4 ± 1.5 1.1 Diffusion (0.60)
AM 10 59.6 ± 4.2 46.9 ± 8.5 0.8 Diffusion (0.25)
AM 20 37.0 ± 4.7 34.7 ± 2.7 0.9 Diffusion (0.69)
AM+ PSC 20 42.9 ± 1.5 52.9 ± 6.9 1.2 Diffusion (0.23)
AM + MQ 20 + 50 57.6 ± 7.9 57.9 ± 8.3 1.0 Diffusion (0.98)
Data is presented as Permeability +/- SEM.
*P values <0.05 are deemed significant in their difference.
MQ: mefloquine, PSC: PSC833, AQ: amodiaquine, ART: artesunate, AM: artemisone.
a Mean Papp for Bas-Ap direction was divided by the Ap-Bas direction.
b Mean Papp of Ap-Bas direction and Bas-Ap direction transport was compared in a two tailed t test to determine p values (N = 3).
doi:10.1371/journal.pone.0152677.t002
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antimalarial. Mefloquine was combined with short acting artemisinin derivatives; artesunate
and artemisone and intermediate acting methylene blue in this study to reflect these possible
clinical practices. The Papp values for Ap-Bas and Bas-Ap directional transport of mefloquine
was not altered when combined with artesunate, artemisone or methylene blue as given in
Table 2. Therefore, passive diffusion of mefloquine is unlikely to be altered by other antimalar-
ial co-treatment illustrating the absence of permeability related drug interactions of
mefloquine.
Amodiaquine. Ap-Bas directional permeability values of amodiaquine were found to be
higher than mefloquine and ranged from 16 to 22 × 10−6 cm/sec (Table 2). At 10 μM, amodia-
quine showed an efflux ratio of 1.3, yet this low efflux ratio is unlikely to represent even a mod-
erate affinity for P-gp. At a higher concentration (100 μM) efflux became exactly 1.0 showing
no net efflux transport. The Papp values for amodiaquine were not altered when co-incubated
with new artemisinin derivative artemisone. The high Papp values indicates high intestinal per-
meability of amodiaquine, therefore any slight efflux transport at lower concentration is
unlikely to affect the extent of drug absorption of amodiaquine.
Methylene blue. Methylene blue exhibited increased Bas-Ap transport with the efflux
ratio of 4.2 at 100 μM. As shown in Table 3, the efflux ratio was further increased to 7.6 when
test drug concentration dropped by half (50 μM). In order to confirm that efflux transport
observed for methylene blue is P-gp mediated, the drug was combined with PSC 833. This
increased the Ap-Bas and decreased the Bas-Ap directional transport of methylene blue
decreasing the overall efflux ratio. However PSC 833 was not able to fully block the efflux trans-
port of methylene blue which suggested involvement of other gastrointestinal efflux mecha-
nisms in addition to P-gp mediated efflux transport.
Therefore methylene blue bidirectional transport was further studied by co-incubating
methylene blue with the potent P-gp and BCRP blocker; GF 120918, an MRP blocker; MK571
and an ATP hydrolysis inhibitor; sodium orthovanadate. All three inhibitors blocked the efflux
transport to a certain extent, reducing the efflux ratio. The efflux ratio of methylene blue was
brought down close to unity when both P-gp and MRP blockers, PSC 833 and MK571, were
Fig 2. A) Ap-Bas (solid square) and Bas-Ap (solid diamond) transport of mefloquine B). Ap-Bas (solid square) and Bas-Ap (solid diamond) transport of
methylene blue alone and Ap-Bas (solid square with dots) plus Bas-Ap (hashed diamond) with PSC833 and Ap-Bas (open circle) plus Bas-Ap (hashed circle)
with PSC833 combined with MK571
doi:10.1371/journal.pone.0152677.g002
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co-incubated with methylene blue which supported the hypothesis that both P-gp and MRP
are involved in efflux transport of methylene blue (Fig 2). Sodium vanadate was unable to fully
block the ATP dependent efflux transport (Table 3).
As shown in Table 3 the overall permeability of methylene blue was found to be low and
Ap-Bas directional transport ranged from 1.6 to 1.8×10−6 cm/sec for 50 and 100 μM, suggest-
ing poor drug permeability.
Artesunate. The Bas-Ap transport of artesunate was slightly higher compared to the Ap-
Bas directional transport with an efflux ratio of 1.2 (Table 2). However as indicated for amodia-
quine such small increase in Bas-Ap transport will have negligible effect on systemic absorp-
tion. The artesunate diffusion was not altered when combined with mefloquine. The Papp
values for Ap- Bas directional transport for artesunate was 10.2 × 10−6 cm/sec. This permeabil-
ity value of artesunate places it in a medium category suggesting passive diffusion contributes
to drug absorption of artesunate, although absorption is likely to be incomplete through the
gastrointestinal tract.
Artemisone. Artemisone is a newly investigated artemisinin derivative and the net trans-
port of artemisone was much higher than the other drugs tested. The Ap-Bas transport ranged
from 37 to 60 × 10−6 cm/sec and Bas-Ap transport ranged from 35 to 47 × 10−6 cm/sec
(Table 2). Therefore the new artemisinin derivative ensures complete drug absorption and
shows much higher passive diffusion than the currently used artesunate. Addition of PSC-833
did not alter the bidirectional transport significantly; therefore artemisone is not subjected to
P-gp mediated drug efflux transport. Artemisone diffusion was not altered when co-incubated
with mefloquine.
P-glycoprotein inducing properties of antimalarials
P-gp regulation was originally tested at concentrations above 100 μMwhich were found to be
toxic to cells when used for multiple days, forcing a reduction in the upper concentration able
to be used in these studies. Nevertheless, a distinct increase in the expression of P-gp was noted
for methylene blue and combinations of artemisone and dihydroartemisinin (Fig 3). However,
similar trends were not observed for artesunate combinations.
Table 3. Apparent permeability (Papp ± SEM) and efflux ratio of methylene blue through Caco-2 cell monolayer.
Drug Conc (μM) + inhibitor(μM) Ap-Bas (10−6 cm/sec) Bas-Ap (10−6 cm/sec) Efflux ratio a Net flow direction (P value b)
MB 100 1.8 ± 0.1 7.7 ± 0.5 4.2 Efflux (<0.001**)
MB+PSC833 100 + 4 2.5 ± 0.1 5.5 ± 0.3 2.2 Efflux (<0.001**)
MB 50 1.6 ± 0.0 12.0 ± 0.2 7.6 Efflux (<0.001**)
MB + PSC833 50 + 4 2.4 ± 0.1 4.0 ± 0.2 1.7 Efflux (<0.001**)
MB+ GF 50 + 4 1.5 ± 0.0 3.4 ± 0.1 2.3 Efflux (<0.001**)
MB + MK 50 + 40 1.1 ± 0.1 3.9 ± 0.2 3.6 Efflux (<0.001**)
MB + PSC + MK 50 + 4 + 40 2.4 ± 0.7 3.2 ± 0.1 1.3 Diffusion (0.36)
MB + GF +MK 50 + 4 + 40 1.1 ± 0.0 1.8 ± 0.1 1.7 Efflux (0.001**)
MB + vanadate 50 + 100 1.6 ± 0.1 4.0 ± 0.2 2.5 Efflux (<0.001**)
Data is presented as permeability +/- SEM.
*P values < 0.05 are deemed significant in their difference.
MB: methylene blue, PSC: PSC833, GF: GF120198, MK: MK571, vanadate: sodium orthovanadate.
a Mean Papp for Bas-Ap direction was divided by the Ap-Bas direction.
b Mean Papp of Ap-Bas direction and Bas-Ap direction transport was compared in a two tailed t test to determine p values (N = 3).
** Significant at the level of P < 0.005
doi:10.1371/journal.pone.0152677.t003
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Discussion
P-gp inhibitory action of antimalarial drugs
Mefloquine at 100 μMwas able to bring about 50% inhibition of efflux driven transport
whereas PSC-833, a potent P-gp transport inhibitor, can completely eradicate P-gp mediated
transport at 4 μM [19]. This puts mefloquine at the lower end of inhibitory affinity. The inher-
ent toxicity of mefloquine precluded the study of inhibitory properties at higher concentrations
(> 100 μM). The volume of the human intestinal lumen is considered to be 2.5 L [34] and at
this volume, the therapeutic doses of 10 to 15 mg/kg/day would attain mefloquine intestinal
concentration between 750 to 1100 μM for a 70 kg adult. This is 7 to 10 fold higher than the
concentration exerting 50% inhibition of the P-gp mediated efflux transport. Therefore at anti-
malarial doses of mefloquine, the complete blockage of P-gp mediated efflux transport of P-gp
substrates could be expected at the gut wall. This finding is consistent with the published litera-
ture and P-gp inhibitory properties of mefloquine were demonstrated in three different in-vitro
cell lines; human CEM tumour cells primed with vinblastine (CEM/VBL), P388 leukaemia
cells (P388/ADR) and immortalised rat brain capillary endothelial cells (GPNT) [35–37].
Counter to our current study, a previous report stated that mefloquine exerts some P-gp
inhibitory properties at concentrations that may be achievable within the circulation [35]. As
our data suggests mefloquine is a relatively less potent P-gp inhibitor at circulating concentra-
tions rather than gut concentration this could at least minimise CNS side effects exerted from
any penetration of the blood brain barrier, as the expectation for our study would suggest poor
P-gp inhibition at low micromolar concentrations.
Amodiaquine, methylene blue, artesunate and artemisone did not exhibit P-gp inhibitory
properties at our test concentrations. In contrast to this, P-gp inhibitory properties of amodia-
quine at 100 and 1000 μM are reported in the literature [38]. However we were unable to test
high concentrations of amodiaquine due to its solubility limitation in physiological pH and co-
solvents, which has also been described previously [39]. There was no prior evidence of P-gp
inhibitory properties for methylene blue and artemisone whereas the limited literature avail-
able on inhibitory properties of artesunate was inconsistent suggesting both presence and
absence of P-gp inhibitory properties between multiple publications [38, 40, 41]. Further stud-
ies involving a wider range of drug concentrations and cell lines may help elucidate better
Fig 3. A) Western blot for 96 hours exposure of 20 μM antimalarials on Caco-2 cell monolayer. Beta actin was used as the reference protein. Lanes 1–15
were loaded with cell lysates of exposure 1)methylene blue, 2)mefloquine, 3)amodiaquine, 4)artesunate, 5)dihydroartemisinin, 6)artemisone, 7)0.5%
ethanol, 8)artesunate plus mefloquine, 9)artesunate plus amodiaquine, 10)artemisone plus mefloquine, 11)artemisone plus amodiaquine, 12)
dihydroartemisinin plus mefloquine, and 13)dihydroartemisinin plus amodiaquine 14) molecular weight marker 15) transfected Hela MDR1 positive control
respectively. B) Regulation of P-gp transporter protein compared to control following 96 hours of antimalarial exposure on confluent Caco-2 cell monolayers.
doi:10.1371/journal.pone.0152677.g003
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understanding of the P-gp inhibitory properties of amodiaquine and artesunate. However use
of high drug concentrations can be directly toxic to cell lines, complicating any interpretation
regarding transporter specific functionality. The apparent discrepancy of inhibitory properties
at low concentration between studies is likely to be an anomaly related to P-gp expression/
activity. Co-incubation of mefloquine with artesunate or artemisone did not demonstrate addi-
tive P-gp inhibitory properties in our Caco-2 cell line. This reaffirms that mefloquine is the
only drug with any P-gp inhibitory properties from the drugs tested.
Efflux transport and permeability of antimalarials
Mefloquine. Equivalent bidirectional transport demonstrated the absence of P-gp medi-
ated drug efflux at concentrations above 10 μM, suggesting that mefloquine is absorbed by pas-
sive diffusion. Counter to our results, a study using cellular accumulation showed 14C
mefloquine to have P-gp substrate activity at nanomolar concentrations [37]. Efflux transport
observed at such low concentrations is unlikely to be clinically significant when it comes to gas-
trointestinal drug absorption but might be relevant at the blood brain barrier. Orally acquired
mefloquine 700 μMwould saturate the efflux transporters resulting in only diffusion like con-
ditions for the drug at the intestinal wall. In the systemic circulation drug concentration would
be lower, so if mefloquine was a P-gp substrate at nanomolar concentration, this would prevent
the drug from accessing the CNS compartment. Certainly there is evidence that high dose mef-
loquine can cause severe dizziness in some patients, especially children, where the circulating
concentrations may be higher [42] saturating protective efflux pumps at the BBB. Such concen-
trations would not last for long, and certainly, the CNS effects are some of the first to dissipate
in susceptible individuals [42].
Information on the oral bioavailability and bidirectional transport of mefloquine in in-vitro
cell lines has not been reported previously. Our Papp values suggests a moderate permeability of
around 50–84% drug absorption of mefloquine based on the FDA biopharmaceutical classifica-
tion system [16].
Mefloquine permeability was not altered when co-incubated with artesunate, artemisone or
methylene blue in this in-vitro system. However a human pharmacokinetic study has shown a
decrease in Cmax of mefloquine when administered concurrently with artesunate [43]. Based
on our findings, this change may not be related to initial permeability.
Amodiaquine. The Ap-Bas directional transport of amodiaquine was found to be higher
than mefloquine conforming to the inherent physiochemical properties of amodiaquine which
favours passive diffusion [44, 45]. There is no published literature on bioavailability of amodia-
quine but it is claimed to have a pharmacokinetic profile similar to that of chloroquine (oral
bioavailability of 78 to 89%) [46, 47]. The high permeability of amodiaquine found in our
study correlates to rapid oral absorption (tmax < 1 hour) of amodiaquine following oral admin-
istration in human [46].
The limited efflux transport (1.3) observed at 10 μMwas not observed at higher concentra-
tions. The efflux observed at 10 μMwould be clinically insignificant as oral antimalarial dosing
result in up to 120 fold higher concentrations saturating P-gp transporter mediated efflux. The
high permeability and lack of P-gp mediated transport of amodiaquine has also been reported
by another study [40]. The high passive permeability is unlikely to be altered when co-adminis-
tered with other drugs as evident by unchanged Papp values of amodiaquine when co-incubated
with artemisone.
Methylene blue. Other than the small molecular size, inherent physicochemical parame-
ters (pKa 0–1, log P -0.9 at pH 7, log D 0.06) of oxidized methylene blue are not conducive to
rapid passive diffusion [48, 49]. Consistent with these properties, a low permeability was
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observed in this study, indicating low cell uptake and drug absorption (< 50%) of methylene
blue can be expected [16].
A positive efflux ratio was observed with methylene blue. It could be reduced by about 50%
when co-incubated with PSC 833, which still left a significant efflux ratio associated with this
drug, implying P-gp and others transporters are continuing to remove methylene blue from
cells. Co-incubation with MK571 and PSC 833 created parity of directional transport suggest-
ing that methylene blue is a joint substrate for both MRP2 as well as P-gp which would limit its
absorption to even lower levels than its weak physicochemical properties would suggest.
Two pharmacokinetics studies conducted in human volunteers have reported contrasting
oral bioavailability values for methylene blue (10% vs 72%), with high bioavailability in one
report due to increased sensitivity of the analytical techniques used [50]. The low bioavailability
found in the first study was apportioned to high first pass elimination [51]. Nevertheless, ABC
transporter mediated efflux transport of methylene could also contribute to this large discrep-
ancy in bioavailability. In the pharmacokinetic study with lower bioavailability, volunteers
were given 100 mg of methylene blue, which would result in gastrointestinal concentration
around 125 μM, a concentration similar to the test concentration used in the present study
[51]. Therefore, it is likely that low in-vivomethylene blue bioavailability observed in this study
is related to the ABC transporters mediated efflux in the gut. The second study, resulted in a 5
fold higher gastrointestinal concentration (625 μM) [50]. This may have saturated efflux trans-
porters allowing better cell accumulation. In the absence of efflux transport, a higher propor-
tion of drug can be expected resulting in higher bioavailability of methylene blue.
One clinical study, in children, used a dose of 12 mg/kg which is between 1.7 [51] and 8 [50]
folds higher than other studies using methylene blue. This high dose study appears to saturate
efflux transport system [52] and this dose of 12mg/kg may be appropriate for management of
malaria to achieve adequate therapeutic concentrations.
Artesunate. Our study showed a moderate permeability for artesunate and this is consis-
tent with an earlier report, where Papp for sodium artesunate was found to be 4×10
−6 cm/sec
[53]. The small efflux transport ratio observed (efflux ratio of 1.5) for artesunate is unlikely to
result in difference in permeability as much higher gut concentration is achieved at therapeutic
dose levels. Some degradation of artesunate to dihydroartemisinin has shown previously at
37°C [54]. This needs to be considered when in-vitro Papp values of artesunate are used to pre-
dict in-vivo drug absorption.
Artemisone. Artemisone has favourable physicochemical parameters to facilitate passive
diffusion [13]. Out of all drug tested, artemisone showed the highest Papp values for both direc-
tions confirming passive permeability and 100% drug absorption most likely before entering the
jejunum [16]. Artemisone has also shown higher in-vivo bioavailability compared to artesunate
in monkeys [14]. P-gp mediated efflux transport was not observed for artemisone in our study,
so it is unlikely that P-gp mediated drug interactions are a concern for this drug. As anticipated,
no change in Papp of artemisone was observed when co-incubated with mefloquine.
P-gp mediated drug interactions
Based on the present study and the previously published literature, it is evident that mefloquine
has P-gp inhibitory properties and could lead to permeability related drug interactions when
co-administered with P-gp substrates. Amodiaquine, artesunate and artemisone did not dem-
onstrate P-gp substrate and inhibitory properties at the therapeutic concentration and are
absorbed following passive diffusion. Similarly mefloquine permeability was by passive diffu-
sion. Therefore it is unlikely for these drugs to have permeability/ drug absorption related drug
interactions in combination therapy. Methylene blue showed ABC transporter (P-gp and
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MRP) mediated drug efflux transport with comparatively higher Km value compared to the
other tested antimalarials. Therefore ABC transporter mediated pharmacokinetic interactions
are likely for methylene blue.
P-gp regulation. Methylene blue incubation alone upregulated the P-gp expression. This
was plausible due to its P-gp substrate nature. P-gp substrates such as vinblastine and some
antiretrovirals have shown P-gp induction properties [55, 56]. It is reported that artemisinin
induces expression of CYP2B6, CYP3A4 and P-gp through the activation of human PXR and
human constitutive androstane receptor (CAR) [57]. We also observed a slight up regulation of
P-gp for artesunate. The molecular structure of mefloquine suggests that it has the ability to
induce P-glycoproteins [58] but this was not observed in our study. Increased expression of P-
gp was observed when artemisone and dihydroartemisinin were co-incubated along with mef-
loquine or amodiaquine. This was not evident with artesunate combinations though. The pos-
sible explanation for this need to be investigated in further studies.
In summary we observed P-gp inhibitory properties for mefloquine at 100 μMwhile amo-
diaquine, methylene blue, artesunate and artemisone did not show P-gp inhibitory properties
at test concentrations. Mefloquine, amodiaquine, artesunate and artemisone did not exhibit P-
gp substrate properties that can be clinically significant and permeated through passive diffu-
sion. The permeability across the gastrointestinal epithelium was found to be low for methy-
lene blue, medium for mefloquine and artesunate and high for amodiaquine and artemisone.
Only methylene blue had P-gp and MRP mediated efflux transport.
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